Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

January 30, 2024

https://www.globenewswire.com/news-release/2024/01/30/2819984/37414/en/Acceptance-of-Ivospemin-SBP-101-Abstract-for-Poster-Presentation-at-American-Association-for-Cancer-Research-AACR.html

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.

Read more at globenewswire.com

Related news for (PBLA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.